Psyence Biomedical (PBM) Stock Soars 200% After White House Ibogaine Order News

TLDR

• PBM stock skyrocketed up to 203.8% on April 16, 2026, following reports that the White House is drafting an executive order to advance ibogaine research.
• The firm increased its Australian clinical trial network from three to five locations for its NPX-5 Phase IIb psilocybin investigation.
• PBM also postponed a previously planned 1-for-6.25 reverse stock split, meaning the stock continues to trade without adjustment.
• The surge is considered a micro-cap momentum play fueled by limited liquidity and speculative trading, not by new fundamental news.
• PBM possesses a market capitalization of only $11.63 million and a GF Score of 20/100, including a profitability rating of 1/10.

(SeaPRwire) –   Psyence Biomedical (PBM) experienced extreme volatility on April 16, 2026. The share price soared over 200% as investor interest spiked on news of a pending White House executive order to support research into ibogaine, a psychedelic substance being investigated for PTSD and other mental health disorders.

Psyence Biomedical Ltd., PBM

PBM ended the trading day with a gain of roughly 203.8%, as reported by Quiver PriceTracker. Earlier estimates from GuruFocus indicated an intraday increase of approximately 105.96%.

The White House’s action indicates a change in the federal government’s stance toward psychedelic-based treatments. Ibogaine has garnered attention as a possible therapy for addiction and trauma, and the executive order is intended to encourage more scientific research.

While PBM does not directly work with ibogaine—its focus is on natural psilocybin—the stock was buoyed by the favorable regulatory outlook for the broader psychedelic sector.

Clinical Trial Expansion Adds to the Buzz

In addition to the broader market news, PBM announced its own development. The company has widened its Australian clinical trial network from three to five sites. This enhancement supports the continuing Phase IIb work for NPX-5, its natural psilocybin candidate intended for Adjustment Disorder in palliative care cancer patients.

The goal of the expansion is to accelerate patient enrollment and maintain dosing throughout the study. This information was submitted to the SEC in an April 2026 Form 6-K filing.

No new data concerning efficacy or safety was published on April 16. Observers suggest the price movement was driven by momentum, with low trading volume intensifying the swing.

The company also verified the delay of a previously communicated 1-for-6.25 reverse stock split. PBM shares will trade without adjustment until a new effective date is established. This decision maintained a smaller share float, potentially contributing to the squeeze-like trading activity.

What the Numbers Say

PBM is a micro-cap company with a market valuation of merely $11.63 million. Prior to the surge, the stock was trading near $5.08—significantly below its 52-week high of $74.94.

Its GF Score is 20 out of 100. It has a financial strength rating of 8/10, but its profitability score is only 1/10. The company lacks a P/E ratio because it is not profitable.

Institutional ownership is minimal. During the fourth quarter of 2025, five funds reduced or closed their positions. Parallel Advisors sold its entire holding of 151,250 PBM shares. UBS Group was the only new institutional investor, purchasing 1,007 shares.

There have been no reports of insider stock purchases or sales in the last year.

The company runs a federally approved psilocybin cultivation facility in Southern Africa and distributes its products to international partners.

As of April 16, 2026, PBM has not yet generated revenue or achieved profitability, and its clinical program is still in mid-stage trials.